Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires
Rhea-AI Filing Summary
Travere Therapeutics, Inc. reported that its chief accounting officer and principal accounting officer, Sandra Calvin, plans to retire after the filing of the company’s Annual Report on Form 10-K expected in February 2027. The company expects Vice President, Controller John Torell, a CFA and CPA, to assume the CAO and PAO roles, with the board planning to appoint him before her retirement to allow for an orderly transition of responsibilities.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Retirement timing: February 2027
Notice date: July 6, 2026
Company headquarters: San Diego, CA 92130
3 metrics
Retirement timing
February 2027
Planned retirement after filing of Annual Report on Form 10-K
Notice date
July 6, 2026
Date CAO provided retirement notice to the company
Company headquarters
San Diego, CA 92130
Principal executive offices address on record
Key Terms
principal accounting officer, forward-looking statements, Risk Factors, internal controls over financial reporting
4 terms
principal accounting officer financial
"Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
forward-looking statements regulatory
"This report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Risk Factors regulatory
"Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”"
Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.
internal controls over financial reporting financial
"responsible for accounting operations, financial reporting, SEC reporting, technical accounting, and internal controls over financial reporting"
Internal controls over financial reporting are the policies, procedures and checks a company uses to make sure its accounting and financial statements are accurate, complete and free from significant error or fraud. They matter to investors because strong controls lower the risk of misleading results or surprise restatements—think of them as a quality checkpoint on a factory line that helps prevent costly defects that could damage a company’s value and reputation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What leadership change did Travere Therapeutics (TVTX) disclose?
Travere Therapeutics disclosed that chief accounting officer and principal accounting officer Sandra Calvin plans to retire after the company files its Form 10-K expected in February 2027. The company plans an orderly transition of these responsibilities to Vice President, Controller John Torell.
When is Travere Therapeutics’ CAO expected to retire?
The chief accounting officer, Sandra Calvin, intends to retire following the filing of Travere Therapeutics’ Annual Report on Form 10-K expected in February 2027. This timing allows the company to manage a planned and structured transition of its principal accounting responsibilities.
Who will succeed the retiring CAO at Travere Therapeutics (TVTX)?
Travere Therapeutics expects Vice President, Controller John Torell to succeed Sandra Calvin as chief accounting officer and principal accounting officer. The board is expected to appoint him to these roles before her retirement to ensure continuity in accounting, reporting, and internal controls oversight.
What experience does John Torell bring to the Travere Therapeutics CAO role?
John Torell has overseen accounting operations, financial and SEC reporting, technical accounting, and internal controls at Travere since 2021. Previously, he held senior finance roles at Pacific Life Insurance Company from 1997 to 2019 and earlier worked as an audit manager with Deloitte.
What forward-looking statements did Travere Therapeutics include in this 8-K?
Travere Therapeutics’ forward-looking statements relate to the planned retirement of Sandra Calvin, the transition plan for the CAO/PAO role, and the timing of these changes. The company notes such statements involve risks, including human capital factors and business needs, which may affect actual outcomes.